HMB-002 - (VELORA Discover)

June 26, 2026: Hemab Therapeutics (NASDAQ: COAG) announced nine presentations at the ISTH 2026 Congress (Paris, July 11–15, 2026) highlighting updates across sutacimig (HMB-001), HMB-002, and the newly announced HMB-003.

Sutacimig (Glanzmann thrombasthenia; Factor VII deficiency expansion): Phase 2 long-term extension data in Glanzmann thrombasthenia show sustained reductions in annualized treated bleeding rate (ATBR), including reported successful use in surgical settings, alongside real-world and natural-history analyses of disease burden. Preclinical data supporting expansion into Factor VII deficiency (FVIID) will be presented; a Phase 2 proof-of-concept/Phase 2b study in FVIID is in progress, with data expected late 2026 or early 2027. Sutacimig has FDA Breakthrough Therapy and EMA PRIME designations (also Fast Track and Orphan Drug in the U.S. are noted), and Phase 3 initiation in GT is planned for 2H 2026.

HMB-002 (Von Willebrand disease): New first-in-human Phase 1/2 data support a subcutaneous, non-replacement approach that elevates endogenous VWF and FVIII with sustained elevations; no thromboembolic events were observed. Multiple-dose assessment is underway.

HMB-003 (plasmin inhibitor; preclinical): Preclinical data describe a long-acting, fatty-acid–conjugated peptide plasmin inhibitor for subcutaneous dosing; showed greater potency than tranexamic acid in a human whole-blood flow model and demonstrated long half-life in preclinical models. First-in-human studies are planned for 2H 2026; preparation for heavy menstrual bleeding studies in 2027 is referenced.